[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hot-flash-due-to-medication\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hot-flash-due-to-medication":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100524269","phase-3-reducing-hot-flashes-in-women-using-endocrine-therapy-100524269",false,"NCT06106529","REDucing Hot FLASHes in Women Using Endocrine Therapy.","A Randomized Intrapatient Cross-over Study to Assess the Efficacy of Oxybutynin Versus Venlafaxine in Reducing Hot Flashes in Women Using Endocrine Therapy After Breast Cancer.","REDFLASH","Inclusion Criteria:\n\n* Pre-, peri- or postmenopausal women of 18 years or above;\n* Indication for endocrine therapy and already started with tamoxifen, aromatase inhibitors or luteinizing hormone-releasing hormone analogues for at least 4 weeks and planning to continue for the duration of the study;\n* Experiencing hot flashes with a minimum of 14 per week for at least 1 month and desire to start a pharmacologic intervention.\n\nExclusion Criteria:\n\n* Pregnant;\n* Breast feeding;\n* Patients who receive chemotherapy or immunotherapy\u002FHER2 antibodies within the prior 8 weeks, and patients scheduled for chemotherapy during the study period;\n* Palliative setting;\n* Use of venlafaxine or any other antidepressants, also including St. John's wort within the previous year;\n* Creatinine clearance \\\u003C 30 ml\u002Fmin;\n* Liver cirrhosis;\n* Use of gabapentin and\u002For calcium channel antagonists within 2 weeks of study entry;\n* Use of oxybutynin before study entry;\n* Use of any other substances or therapies for the treatment of hot flashes, for instance acupuncture.","FEMALE","18 Years",{"count":20,"type":21},260,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The goal of this randomized intrapatient cross-over study is to assess the efficacy of oxybutynin versus venlafaxine in reducing hot flashes in women using endocrine therapy after breast cancer.\n\nThe objectives it aims to answer are:\n\n* To assess the efficacy of oxybutynin versus venlafaxine in reducing hot flashes in women using endocrine therapy after breast cancer\n* To assess side effects of oxybutynin versus venlafaxine.\n* To assess the personal preference of women for oxybutynin versus venlafaxine in reducing hot flashes.\n* To assess quality of life of women when reducing hot flashes in women using endocrine therapy after breast cancer.\n\nParticipants will fill-out a patient diary during 15 weeks total on a daily basis and receive an (online) questionnaire three times total.\n\nResearchers will compare two groups (venlafaxine group versus oxubutynine group) to assess its efficacy concerning hot flashes.",[27,28],"Breast Cancer","Hot Flash Due to Medication","RECRUITING","2025-01-31",{"date":32,"type":33},"2025-02-04","ACTUAL",{"date":35,"type":33},"2024-10-03",{"date":37,"type":21},"2029-01-01",{"name":39,"class":40},"Reinier de Graaf Groep","OTHER"]